Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

100 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Pembrolizumab versus chemotherapy for microsatellite instability-high or mismatch repair-deficient metastatic colorectal cancer (KEYNOTE-177): final analysis of a randomised, open-label, phase 3 study.
Diaz LA Jr, Shiu KK, Kim TW, Jensen BV, Jensen LH, Punt C, Smith D, Garcia-Carbonero R, Benavides M, Gibbs P, de la Fourchardiere C, Rivera F, Elez E, Le DT, Yoshino T, Zhong WY, Fogelman D, Marinello P, Andre T; KEYNOTE-177 Investigators. Diaz LA Jr, et al. Among authors: fogelman d. Lancet Oncol. 2022 May;23(5):659-670. doi: 10.1016/S1470-2045(22)00197-8. Epub 2022 Apr 12. Lancet Oncol. 2022. PMID: 35427471 Free PMC article. Clinical Trial.
Cost-effectiveness of pembrolizumab for the first-line treatment of patients with unresectable or metastatic MSI-H/dMMR colorectal cancer in the United States.
Aguiar-Ibáñez R, Hardern C, van Hees F, Lee D, Patel A, Chhabra N, Baluni G, Amonkar M, Lai Y, Xu R, Massaad R, Fogelman D. Aguiar-Ibáñez R, et al. Among authors: fogelman d. J Med Econ. 2022 Jan-Dec;25(1):469-480. doi: 10.1080/13696998.2022.2043634. J Med Econ. 2022. PMID: 35184650 Free article.
Family history as a marker of platinum sensitivity in pancreatic adenocarcinoma.
Fogelman D, Sugar EA, Oliver G, Shah N, Klein A, Alewine C, Wang H, Javle M, Shroff R, Wolff RA, Abbruzzese JL, Laheru D, Diaz LA Jr. Fogelman D, et al. Cancer Chemother Pharmacol. 2015 Sep;76(3):489-498. doi: 10.1007/s00280-015-2788-6. Epub 2015 Jul 1. Cancer Chemother Pharmacol. 2015. PMID: 26126726 Free PMC article.
Phase II study of nab-paclitaxel in refractory small bowel adenocarcinoma and CpG island methylator phenotype (CIMP)-high colorectal cancer.
Overman MJ, Adam L, Raghav K, Wang J, Kee B, Fogelman D, Eng C, Vilar E, Shroff R, Dasari A, Wolff R, Morris J, Karunasena E, Pisanic TR 2nd, Azad N, Kopetz S. Overman MJ, et al. Among authors: fogelman d. Ann Oncol. 2018 Jan 1;29(1):139-144. doi: 10.1093/annonc/mdx688. Ann Oncol. 2018. PMID: 29069279 Free PMC article. Clinical Trial.
Pathologic response to preoperative chemotherapy: a new outcome end point after resection of hepatic colorectal metastases.
Blazer DG 3rd, Kishi Y, Maru DM, Kopetz S, Chun YS, Overman MJ, Fogelman D, Eng C, Chang DZ, Wang H, Zorzi D, Ribero D, Ellis LM, Glover KY, Wolff RA, Curley SA, Abdalla EK, Vauthey JN. Blazer DG 3rd, et al. Among authors: fogelman d. J Clin Oncol. 2008 Nov 20;26(33):5344-51. doi: 10.1200/JCO.2008.17.5299. Epub 2008 Oct 20. J Clin Oncol. 2008. PMID: 18936472
The Sequential Radiographic Effects of Preoperative Chemotherapy and (Chemo)Radiation on Tumor Anatomy in Patients with Localized Pancreatic Cancer.
Perri G, Prakash L, Malleo G, Caravati A, Varadhachary GR, Fogelman D, Pant S, Koay EJ, Herman J, Maggino L, Milella M, Kim M, Ikoma N, Tzeng CW, Salvia R, Lee JE, Bassi C, Katz MHG. Perri G, et al. Among authors: fogelman d. Ann Surg Oncol. 2020 Oct;27(10):3939-3947. doi: 10.1245/s10434-020-08427-4. Epub 2020 Apr 7. Ann Surg Oncol. 2020. PMID: 32266574 Free PMC article.
FOLFOXIRI Versus Doublet Regimens in Right-Sided Metastatic Colorectal Cancer: Focus on Subsequent Therapies and Impact on Overall Survival.
Jácome AA, Kee B, Fogelman D, Dasari A, Shureiqi I, Raghav K, Morris V, Johnson B, Overman M, Wolff R, Kopetz S, Rogers J, Ahmed SU, Mehdizadeh A, Rothschild N, Eng C. Jácome AA, et al. Among authors: fogelman d. Clin Colorectal Cancer. 2020 Dec;19(4):248-255.e6. doi: 10.1016/j.clcc.2020.05.010. Epub 2020 Jun 5. Clin Colorectal Cancer. 2020. PMID: 32665092
Comprehensive Clinical and Molecular Characterization of KRAS G12C-Mutant Colorectal Cancer.
Henry JT, Coker O, Chowdhury S, Shen JP, Morris VK, Dasari A, Raghav K, Nusrat M, Kee B, Parseghian C, Pant S, Jeyakumar N, Zhu L, Nishioka Y, Fogelman D, Wolff RA, Hong D, Overman MJ, Vauthey J, Kopetz S, Johnson B. Henry JT, et al. Among authors: fogelman d. JCO Precis Oncol. 2021 Apr 6;5:PO.20.00256. doi: 10.1200/PO.20.00256. eCollection 2021. JCO Precis Oncol. 2021. PMID: 34250391 Free PMC article.
Assessment of Clinical Response Following Atezolizumab and Bevacizumab Treatment in Patients With Neuroendocrine Tumors: A Nonrandomized Clinical Trial.
Halperin DM, Liu S, Dasari A, Fogelman D, Bhosale P, Mahvash A, Estrella JS, Rubin L, Morani AC, Knafl M, Overeem TA, Fu SC, Solis LM, Parra Cuentas E, Verma A, Chen HL, Gite S, Subashchandrabose P, Dervin S, Schulze K, Darbonne WC, Yun C, Wistuba II, Futreal PA, Woodman SE, Yao JC. Halperin DM, et al. Among authors: fogelman d. JAMA Oncol. 2022 Jun 1;8(6):904-909. doi: 10.1001/jamaoncol.2022.0212. JAMA Oncol. 2022. PMID: 35389428 Free PMC article. Clinical Trial.
100 results